Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAALAD2 | Q9Y3Q0 | 10/20 | 0.54 |
| ▸ | ESR1 | P03372 | 2/20 | 0.53 |
| ▸ | PGR | P06401 | 2/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.53 |
| ▸ | VDR | P11473 | 1/20 | 0.49 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.45 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.44 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.44 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15828667 | 0.94 | ESR1 (0.51) | NAALAD2ESR1PGRESR2VDR | |
| SCHEMBL12122167 | 0.89 | NAALAD2 (0.49) | NAALAD2ESR1PGRESR2VDR | |
| SCHEMBL20647847 | 0.88 | NAALAD2 (0.50) | NAALAD2ESR1PGRESR2VDR | |
| SCHEMBL22958014 | 0.83 | ESR1 (0.47) | NAALAD2ESR1PGRESR2VDR | |
| SCHEMBL18025617 | 0.83 | NAALAD2 (0.52) | NAALAD2ESR1PGRESR2VDR | |
| SCHEMBL19365089 | 0.81 | TSG101 (0.56) | NAALAD2PRMT5WDR77 | |
| SCHEMBL24910738 | 0.77 | NAALAD2 (0.63) | NAALAD2CXCR4NR1H2FTOFOLH1 | |
| SCHEMBL21695190 | 0.76 | FTO (0.64) | NAALAD2NR1H2FTOJAK2KEAP1 | |
| SCHEMBL15828661 | 0.75 | TSG101 (0.55) | NAALAD2PRMT5WDR77 | |
| SCHEMBL25711649 | 0.74 | NAALAD2 (0.60) | NAALAD2CXCR4NR1H2FTOJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9937267-B2 | Methods of treating cancer using compounds containing a vascular disrupting agent | INCANTHERA LTD (GB) | 2018-04-10 | — | — | US | disclosed |
| US-20170266307-A1 | Methods Of Treating Cancer Using Compounds Containing A Vascular Disrupting Agent | ELLIPSES PHARMA LIMITED (GB) | 2017-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170266307-A1 | Methods Of Treating Cancer Using Compounds Containing A Vascular Disrupting Agent | MMP10, MMP25, MMP26 | NAALAD2 438/4885ESR1 3588/4885PGR 1891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.